Tredje AP fonden Lowers Stake in DaVita Inc. (NYSE:DVA)

Tredje AP fonden decreased its holdings in DaVita Inc. (NYSE:DVA) by 1.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 8,848 shares of the company’s stock after selling 135 shares during the quarter. Tredje AP fonden’s holdings in DaVita were worth $1,226,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of DVA. Blue Trust Inc. raised its stake in shares of DaVita by 58.6% during the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after buying an additional 78 shares during the period. Newbridge Financial Services Group Inc. acquired a new position in DaVita during the fourth quarter worth $30,000. Principal Securities Inc. purchased a new position in DaVita during the fourth quarter valued at $37,000. Family Firm Inc. acquired a new stake in shares of DaVita in the second quarter valued at about $43,000. Finally, Versant Capital Management Inc increased its stake in shares of DaVita by 90.6% during the second quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock worth $45,000 after purchasing an additional 155 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Insider Buying and Selling

In other DaVita news, CEO Javier Rodriguez sold 32,176 shares of DaVita stock in a transaction on Monday, August 26th. The stock was sold at an average price of $155.93, for a total value of $5,017,203.68. Following the sale, the chief executive officer now owns 905,659 shares in the company, valued at $141,219,407.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Javier Rodriguez sold 32,176 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $155.93, for a total transaction of $5,017,203.68. Following the completion of the sale, the chief executive officer now directly owns 905,659 shares of the company’s stock, valued at approximately $141,219,407.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Joel Ackerman sold 64,029 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the completion of the sale, the chief financial officer now owns 111,481 shares in the company, valued at $17,286,243.86. The disclosure for this sale can be found here. Over the last three months, insiders sold 173,482 shares of company stock worth $27,387,069. Company insiders own 2.00% of the company’s stock.

DaVita Stock Up 0.5 %

Shares of DVA opened at $164.00 on Friday. The stock has a fifty day simple moving average of $147.19 and a two-hundred day simple moving average of $140.85. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94. The company has a market capitalization of $14.38 billion, a PE ratio of 18.64, a price-to-earnings-growth ratio of 0.95 and a beta of 0.87. DaVita Inc. has a 52-week low of $71.51 and a 52-week high of $166.04.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.47 by $0.12. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The company had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.15 billion. During the same period in the previous year, the firm earned $2.08 earnings per share. DaVita’s quarterly revenue was up 6.2% compared to the same quarter last year. As a group, equities analysts forecast that DaVita Inc. will post 9.99 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. TD Cowen lifted their price objective on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. UBS Group lifted their price target on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Truist Financial raised their price objective on DaVita from $150.00 to $165.00 and gave the company a “hold” rating in a report on Tuesday, August 20th. Bank of America increased their target price on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday, August 7th. Finally, StockNews.com lowered shares of DaVita from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $157.00.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.